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Enterobacteriaceae peritonitis is a serious complication in
peritoneal dialysis (PD), but the clinical course of PD-related
Enterobacteriaceae peritonitis remains unclear. We reviewed
all Enterobacteriaceae peritonitis in our dialysis unit from
1995 to 2004. During this period, there were 1748 episodes
of peritonitis recorded; 210 episodes (12.0%) in 123 patients
were caused by Enterobacteriaceae. The most common
species was Escherichia coli, accounting for 111 episodes. The
primary response rate was 84.8% and complete cure rate was
58.1%. The presence of exit site infection was associated with
a lower complete cure rate (43.2 versus 61.3%, P¼ 0.034).
A total of 82 episodes (39.0%) did not respond to single
antibiotic treatment despite sensitivity in vitro, and a second
antibiotic was added. Patients treated with two antibiotics
had a marginally lower risk of relapse and recurrence than
those with one antibiotic (21.4 versus 36.1%, P¼ 0.051). The
episodes that had recent antibiotic therapy had a marginally
lower complete cure rate (49.3 versus 62.8%, P¼ 0.06). There
was a gradual increase in the prevalence of resistance to
several commonly used antibiotics over the years. Recent
antibiotic therapy was associated with resistance to
cefotaxime, ceftazidime, cefoperazone/sulbactam, and
piperacillin/tazobactam. We conclude that Enterobacteriaceae
peritonitis is a serious complication of PD. Recent antibiotic
therapy is the major risk factor of antibiotic resistance. Exit
site infection, and probably recent antibiotic therapy,
is associated with poor therapeutic response. Contrary
to the current recommendation, treatment with two
antibiotics may reduce the risk of relapse and recurrence.
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Peritonitis is a serious complication of peritoneal dialysis
(PD).1–3 It is probably the most important cause of technique
failure in PD.2–5 Although Gram-positive organisms are the
most common bacteriologic cause of PD-related peritoni-
tis,1,6 the incidence is falling because of advances in PD
connectology.5,7,8 Gram-negative organisms now account for
20–30% of all PD-related peritonitis.5,9 Among all Gram-
negative organisms, those from the family Enterobacteriaceae
were the most common causes of PD-related peritonitis.5,10
Enterobacteriaceae are a large, heterogeneous family of
Gram-negative bacteria. Enterobacteriaceae often are labeled
as ‘enteric bacteria’ because of their predilection for intestinal
colonization. According to the latest classification by
Ewing,11 a number of genera within the family are major
human intestinal pathogens (e.g., Shigella, Salmonella), and
several are normal colonizers of the human gastrointestinal
tract (e.g., Escherichia, Klebsiella).12 Peritonitis caused by
Enterobacteriaceae may be due to touch contamination, exit
site infection or possibly a bowel source, such as constipation,
colitis or transmural migration, but the etiology is often
unclear.13–16
The current guideline for the management of PD
peritonitis by the Ad Hoc Advisory Committee on Peritonitis
Management recommends single effective antibiotics therapy,
for example, a third-generation cephalosporin, for 2–3
weeks.13 However, this recommendation was largely based
on small clinical studies.14,15 The clinical course of PD-
related Enterobacteriaceae peritonitis remains unclear. In
Hong Kong, PD is the first-line renal replacement therapy for
all patients with end-stage renal disease.3 Patients are
switched to long-term hemodialysis only when they have
ultrafiltration failure or peritoneal sclerosis. This policy pro-
vides an excellent opportunity for us to examine the clinical
feature and therapeutic outcome of Enterobacteriaceae
peritonitis in a large unselected group of PD patients.
RESULT
From 1995 to 2004, 1748 episodes of PD-related peritonitis
were recorded in our unit. The overall peritonitis rate was
19.8 patient-month per episode. We reviewed 210 episodes
of Enterobacteriaceae peritonitis in 123 patients. Their
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2006 International Society of Nephrology
Received 20 June 2005; revised 27 July 2005; accepted 8 November
2005; published online 8 February 2006
Correspondence: CC Szeto, Department of Medicine & Therapeutics, Prince
of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong,
China. E-mail: ccszeto@cuhk.edu.hk
Kidney International (2006) 69, 1245–1252 1245
demographic and baseline clinical data are summarized in
Table 1. All patients had cloudy dialysis effluent. Other
presenting symptoms included abdominal pain (98.1%),
fever (32.4%), diarrhea (24.8%) and vomiting (15.7%). The
presenting symptoms were similar to the peritonitis episodes
caused by other organisms (details not shown).
The species of Enterobacteriaceae isolated from PD
effluent (PDE) are summarized in Table 2. The most
common species was Escherichia coli. In 37 episodes
(17.6%), there was concomitant exit site infection. The
bacteriologic cause of exit site infection is summarized in
Table 3 and there was no obvious difference in the
distribution of organism to our overall PD population. The
same bacterial species, however, was isolated only in five
episodes (2.4%), while another species of Enterobacteriaceae
was isolated in another five episodes. There was a history of
antibiotic therapy within 30 days prior to the onset of
Enterobacteriaceae peritonitis in 73 episodes (34.8%).
Antibiotics were given in 21 cases (10.0%) for a recent
peritonitis episode by other organisms, in 37 cases (17.6%)
for recent exit site infection and in 15 cases (7.1%) for
unrelated medical reasons. In 16 cases (7.6%), the patient
received two or more antibiotics within 30 days prior to the
onset of Enterobacteriaceae peritonitis.
Clinical outcome
The clinical outcome is summarized in Figure 1. The overall
primary response rate was 84.8%, and the complete cure rate
was 58.1%. Of the 210 episodes, 82 (39.0%) did not respond
to single antibiotic treatment despite sensitivity in vitro, and
a second antibiotic was added. For the 122 episodes that
responded to a single antibiotic, 44 (36.1%) developed
relapse or recurrence within 4 weeks of completion of
therapy. On the other hand, for the 56 episodes that
responded to two antibiotics, only 12 (21.4%) developed
relapse or recurrence (w2 test, P¼ 0.051).
The initial antibiotic regimen is summarized in Figure 2;
the primary response rate and complete cure rate of
individual regimen are summarized in Figure 3. Episodes
that received a third- or fourth-generation cephalosporin as
part of the initial antibiotic regimen had higher primary
response rates than the episodes that received aminoglycoside
initially (87.9 versus 73.2%, P¼ 0.02). However, there was no
difference in their complete cure rates (61.1 versus 53.7%,
P¼ 0.4). The presence of exit site infection of all cause was
Table 1 | Baseline characteristics of the patients (no. of
patients=123)
Sex (M:F) 56:67
Age (years) 57.8711.8
Duration of dialysis (months) 50.2736.3
Body height (m) 1.5770.16
Body weight (kg) 57.2710.2
Diagnosis (no. of cases (%))
Glomerulonephritis 37 (30.1%)
Diabetes 31 (25.2%)
Hypertension 8 (6.5%)
Polycystic 9 (7.3%)
Obstruction 6 (4.9%)
Others/unknown 32 (26.1%)
Major comorbidity (no. of cases)
Coronary heart disease 37 (30.1%)
Congestive heart failure 35 (28.5%)
Peripheral vascular disease 13 (10.6%)
Cerebrovascular disease 20 (16.3%)
Dementia 8 (6.5%)
Chronic pulmonary disease 7 (5.7%)
Connective tissue disorder 9 (7.3%)
Peptic ulcer disease 10 (8.1%)
Mild liver disease 29 (23.6%)
Diabetes 38 (30.9%)
Hemiplegia 20 (16.3%)
Moderate or severe renal disease 123 (100%)
Diabetes with end-organ damage 31 (25.2%)
Any tumor, leukemia, lymphoma 11 (8.9%)
Moderate or severe liver disease 7 (5.7%)
Metastatic solid tumor 0
AIDS 0
Charlson index score 4.171.9
Table 2 | Summary of bacterial species
Bacterial species No. of cases (%)
Escherichia coli 111 (52.9%)
Klebsiella species
Klebsiella pneumoniae 31 (14.8%)
Klebsiella aerogenes 11 (5.2%)
Klebsiella oxytoca 4 (1.9%)
Other Klebsiella species 11 (5.2%)
Enterobacter species
Enterobacter cloacae 5 (2.4%)
Enterobacter gergoriae 2 (1.0%)
Other Enterobacter species 5 (2.4%)
Serratia species
Serratia marcescens 12 (5.7%)
Other Serratia species 6 (2.9%)
Citrobacter species 10 (4.8%)
Morganella species 1 (0.5%)
Proteus species 1 (0.5%)
Total 210
Table 3 | Summary of bacterial species causing exit site
infection (number of cases=37)
Organisms identified No.
Staphylococcus aureus 11a
Coagulase-negative staphylococcal species 1
Diphtheroids 1
E. coli 3
Other Enterobacteriaceae 7
Pseudomonas species 5
Stenotrophomonas species 1
Polymicrobial 5
No growth 3
aSix of them were methicillin-resistant Staphylococcus aureus.
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associated with a lower complete cure rate (43.2 versus
61.3%, P¼ 0.034) but not primary response rate (89.2 versus
83.8%, P¼ 0.3). The episodes that had recent antibiotic
therapy had a marginally lower complete cure rate than the
others (49.3 versus 62.8%, P¼ 0.06), but the primary
response rate was similar (84.9 versus 84.7%, P¼ 0.9). The
primary response rate and complete cure rate were not
associated with age, sex, duration of dialysis, underlying renal
diagnosis or diabetic status (details not shown).
A total of 21 patients (10.0%) died within 1 month after
the onset of Enterobacteriaceae peritonitis. The causes of
death were Enterobacteriaceae peritonitis per se (11 cases),
acute myocardial infarction (five cases), nosocomial pneumo-
nia (two cases), liver failure (two cases) and cerebrovascular
disease (one case).
Enterobacteriaceae peritonitis
(210 cases)
Died within 5 days 
(six cases)
PDE clear-up with one antibiotic
(122 cases)
Suboptimal response to one antibiotic;
second agent added
(82 cases)
Died within 5 days 
(nine cases)
No response by day–10;
catheter removed
(17 cases)
PDE clear-up with 
two antibiotics
(56 cases)
Died within 1 month 
(six cases)
Catheter reinserted
back to PD 
(eight cases)
Failed catheter 
reinsertion;
long-term HD 
(three cases)
Relapse 
(seven cases)
Recurrence 
(five cases)
Cure 
(44 cases)
Relapse 
(23 cases)
Recurrence 
(21 cases)
Cure 
(78 cases)
Repeat peritonitis 
(12 cases)
Repeat peritonitis 
(eight cases)
Figure 1 | Summary of clinical outcome.
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Figure 2 | Initial antibiotic regimen.
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repeat peritonitis after antibiotic treatment was completed.
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A total of 20 episodes (9.5%) developed repeat peritonitis
with the same organism more than 4 weeks after completion
of antibiotic therapy (see Figure 1). The time frame of
developing repeat peritonitis is summarized in Figure 4.
Although six episodes (30%) of repeat peritonitis developed
within 3 months, the remaining episodes occurred evenly in
the subsequent months, and five episodes (25%) developed
more than a year after the index episode.
Epidemiology over 10 years
The incidence rate of Enterobacteriaceae peritonitis in our
unit from 1995 to 2004 is summarized in Figure 5. After a
marked decline from 1995 to 1997, the incidence of
Enterobacteriaceae peritonitis remained static over the
subsequent years. During the 10 years of observation period,
although the complete cure rate remained static, there was a
progressive decline in primary response rate and an
increasing need of using two antibiotics for treatment
(Figure 6).
We further reviewed the profile of antibiotic resistance in
51 isolates of E. coli and Klebsiella species, the two most
common causes of Enterobacteriaceae peritonitis, since 2001.
The overall prevalence of resistance to various antibiotics is
summarized in Table 3. From 2001 to 2004, we observed a
gradual increase in the prevalence of resistance to cephalothin
and cefuroxime but not ceftazidime (Figure 7a). There was
also a slight increase in the prevalence of resistance to
netilmicin or gentamicin (Figure 7b), while the prevalence of
resistance to ciprofloxacin remained constant (details not
shown). Recent antibiotic therapy was associated with
resistance to cefotaxime, ceftazidime, cefoperazone/sulbac-
tam, piperacillin/tazobactam but not other antibiotics (see
Table 4).
From 1999, seven of the 103 isolates (6.8%) of E. coli and
Klebsiella species were positive for extended spectrum
b-lactamase (ESBL). Their clinical outcome is summarized
in Table 5. Four of the seven cases had recent antibiotic
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Figure 5 | Incidence of Enterobacteriaceae peritonitis over 10
years.
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Figure 6 | Change in clinical outcome of Enterobacteriaceae
peritonitis over 10 years: (a) primary response rate and complete
cure rate and (b) percentage of cases that required combined
antibiotic therapy.
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Figure 7 | Prevalence of antibiotic resistance since 2001:
(a) b-lactam group and (b) other antibiotics.
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therapy. Although the number of cases was small and no
definite conclusion could be made, three of the seven cases
had complete cure, which was not substantially lower than
the overall result. All isolates were sensitive to imipenem/
cilastatin in vitro. However, only one of the five cases treated
with an aminoglycoside plus imipenem/cilastatin had
complete cure.
DISCUSSION
In this case series, we examined 210 consecutive episodes of
Enterobacteriaceae peritonitis in our unit from 1995 to 2004.
To the best of our knowledge, this is the largest series on PD
peritonitis caused by this family of common Gram-negative
bacteria. Since this is a retrospective study, many of the cases
might not be managed according to contemporary guide-
lines.13,17 The course of these cases, nevertheless, may
improve our understanding on the clinical behavior of this
complication.
Enterobacteriaceae peritonitis accounted for 12.0% of all
PD-related peritonitis in the present study. The incidence was
similar to other reported series.10,13–16 Since this is a
retrospective study, we cannot affirm the underlying cause
of the Enterobacteriaceae peritonitis. In general, peritonitis
caused by Enterobacteriaceae may be due to touch contam-
ination, exit site infection or possibly a bowel source, such as
constipation, colitis or transmural migration, but the etiology
is often unclear.13–16 Nearly half of our patients presented
with diarrhea, nausea or vomiting in addition to cloudy
dialysis effluent. However, it is difficult to verify whether
these gastrointestinal symptoms represented the cause or
effect of peritonitis.
In the present study, recent antibiotic therapy and
concomitant exit site infection were important risk factors
of poor treatment response. The result is similar to our
previous report on Pseudomonas peritonitis.18 The high
prevalence of recent antibiotic therapy and exit site infection
in our series also suggests that they are risk factors of
developing Enterobacteriaceae peritonitis, but formal statis-
tical analysis is not possible without a proper control group.
Nevertheless, a survey of our unit on 31 December 2004
revealed that 41 of the 297 PD patients (13.8%) had
antibiotic therapy within 30 days (CC Szeto, unpublished
data) as compared to 34.8% of the patients with Enter-
obacteriaceae peritonitis. Since all patients with exit site
infection also received antibiotic therapy, it remains un-
known whether both conditions were independent risk
factors of Enterobacteriaceae peritonitis. We did not identify
any other risk factor of developing Enterobacteriaceae
peritonitis; the patients in the present study had similar
prevalence of diabetes or other comorbid conditions as
compared to the whole PD population reported in our
previous studies.3,19
Most of the episodes in the present study were initially
treated by an aminoglycoside or third- or fourth-generation
cephalosporin. We found that the primary response rate of
the cases treated initially with cephalosporin was higher than
those with aminoglycoside initially. Although their complete
cure rates were not statistically different, the higher primary
response rate with cephalosporin is certainly a desirable effect
because the peritoneum as dialysis membrane may be better
preserved.20,21
Table 4 | Prevalence of antibiotic resistance
Antibiotic
No. of
cases (%)a
Recent antibiotic
therapy, no. of cases (%)b
Cephalosporins
Cephalothin 39 (76.5%) 11 (28.2%)
Cefuroxime 11 (21.6%) 5 (45.5%)
Cefotaxime 7 (13.7%) 4 (57.1%)*
Ceftazidime 4 (7.8%) 3 (75.0%)*
Cefoperazone/sulbactam 6 (11.8%) 4 (66.7%)*
Other b-lactam antibiotics
Ampicillin 35 (68.6%) 8 (22.9%)
Amoxycillin/clavulanate 11 (21.6%) 4 (36.4%)
Piperacillin/tazobactam 5 (9.8%) 4 (80.0%)*
Imipenem/cilastatin 0
Aminoglycosides
Netilmicin or gentamicin 10 (19.6%) 2 (20.0%)
Amikacin 0
Others
Ciprofloxacin 12 (23.5%) 3 (25.0%)
Cotrimoxazole 18 (35.3%) 5 (27.8%)
Total 51
*Po0.05 by Fisher’s exact test.
aPercentage of all bacterial isolates tested.
bPercentage of resistant isolates with recent antibiotic therapy.
Table 5 | Clinical outcome of patients with ESBL-producing Enterobacteriaceae peritonitis
Case # Sex Age (years) Bacterial species Antibiotic regimena Outcome
1 M 62 E. coli Ceftazidime-piperacillin/tazobactam+ciprofloxacin Complete cure
2 F 68 E. coli Netilmicin+ceftazidime Complete cure
3 F 54 K. pneumoniae Ceftazidime-netilmicin+imipenem/cilastatin Complete cure
4 M 71 K. pneumoniae Imipenem/cilastatin+netilmicin Catheter removed, reinsertion successful
5 F 71 E. coli Ceftazidime-amikacin+imipenem/cilastatin Catheter removed and failed reinsertion
6 F 68 E. coli Ceftazidime-gentamicin+imipenem/cilastatin Catheter removed, diedb before reinsertion
7 F 73 Klebsiella species Netilmicin+imipenem/cilastatin Diedc
aThe first antibiotic in each row denotes the initial antibiotic for coverage of Gram-negative organisms.
bDied due to persistent peritonitis.
cDied due to myocardial infarct.
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However, we believe the more important observation is
that patients treated with two antibiotics had a lower risk of
relapse and recurrence than those with one antibiotic (see
Figure 1), although the difference just falls short of statistical
significance. Notably, patients treated with two antibiotics
were those who did not respond promptly to the first agent
and should, in all probability, be more severe, and had a
worse prognosis. Although the current guideline suggests that
a single agent is generally adequate for Enterobacteriaceae
peritonitis,13 double antibiotics has been the standard for
Pseudomonas peritonitis.13,17 Our findings suggest that the
treatment of Enterobacteriaceae peritonitis should probably
also move in that direction.
Although we only have data on antibiotic sensitivity from
2001, we observe an increasing prevalence of antibiotic
resistance over these years (see Table 4). Some inferences
could be made. Firstly, the general increase in antibiotic
resistance was possibly a result of the liberal prescription of
antibiotics in the primary-care setting, a common phenom-
enon in Hong Kong.22 It is interesting to note that the
prevalence of resistance to common antibiotics, such as
cephalothin and oral cefuroxime, increased from 2001 to
2004 (Figure 7), while resistance rate to newer agents, such as
ceftazidime, remained static. This observation also argues
against the possibility that bacteria in a dialysis unit develop
resistance to the first-line antibiotic used for the treatment of
peritonitis with time. In fact, recent antibiotic usage was the
major risk factor of resistance to those newer agents (Table 4).
Clinicians should be aware of the history of recent antibiotic
treatment and consider possible resistant organisms early.
In the present series, we reviewed the clinical course of the
seven episodes of Enterobacteriaceae peritonitis caused by
ESBL-producing organisms. Although ESBL-producing bac-
teria are of rising concern in recent years, related literature on
PD-related peritonitis is scarce. In general, ESBLs confer
resistance to ceftazidime, cefotaxime, ceftriaxone, aztreonam,
and other oxyimino-b-lactams, and are most often found in
Klebsiella species and E. coli, although they have also been
detected in many other Gram-negative pathogens. It should
be noted that the prevalence of ESBL is probably under-
estimated because detection in clinical laboratories is
imperfect.23 Traditionally, carbapenems are the ideal agents
for therapy.23 In fact, none of the isolates in our present study
was resistant to imipenem/cilastatin. However, the in vivo
response was less than impressive. It is now recognized that
the variety of b-lactamases that confer resistance to
carbapenems is increasing.24 Since imipenem/cilastatin has
been the first-line antibiotic for the treatment of PD-related
peritonitis for some time,25 its extensive use is likely to be
followed by the selection of pathogens resistant to this agent.
It is also important to note that there are no b-lactams in
development that can treat infections with organisms
producing some of the new b-lactamases.23 Available agents
need to be used judiciously and infection-control measures
implemented in outbreak situations to prevent the further
spread of this pathogens. On the other hand, Bernardini
et al.26 recently reported a multicenter double-blinded
randomized control trial comparing daily application of
gentamicin and mupirocin cream to the catheter exit site. In
this study, gentamicin cream reduced Gram-negative catheter
infections by more than 50%, and reduced peritonitis by
35%, particularly those caused by Gram-negative organ-
isms.26 Gentamicin cream for exit site care should be
considered in high-risk cases or in centers with a high
incidence of Enterobacteriaceae peritonitis.
In summary, Enterobacteriaceae peritonitis is a serious
complication of peritoneal dialysis. Recent antibiotic therapy
is the major risk factor of antibiotic resistance. Exit site
infection, and probably recent antibiotic therapy, is asso-
ciated with poor therapeutic response to antibiotics. Con-
trary to the current recommendation, treatment with two
antibiotics may reduce the risk of relapse and recurrence.
MATERIALS AND METHODS
All episodes of continuous ambulatory peritoneal dialysis peritonitis
in our unit from 1995 to 2004 were reviewed. The diagnosis of
peritonitis was based on at least two of the following:27,17 (a)
abdominal pain or cloudy PDE; (b) leukocytosis in PDE (WBC
4100/ml); and (c) positive Gram stain or culture from PDE.
Episodes with peritoneal eosinophilia but negative bacterial culture
were excluded. Exit site infection was diagnosed when there was
purulent drainage, with or without erythema, from the exit site.28
In the 10 years of study period, 1748 episodes of peritonitis were
recorded; 282 episodes (16.1%) were caused by Enterobacteriaceae.
A total of 72 episodes was excluded from analysis because PDE
culture showed mixed bacterial growth. The case records of the
remaining 210 episodes in 123 patients were reviewed. The
demographic characteristics, underlying medical conditions, pre-
vious peritonitis, recent antibiotic therapy, antibiotic regimen for
the peritonitis episode, requirement of Tenckhoff catheter removal
and clinical outcome were examined.
Microbiological investigations
Bacterial culture of PDE was performed by BacTAlerts bottles
(Organon Teknika Corporation, Durham). Species identification
was performed by the API 20E identification system (BioMerieux,
Marcy l’Etolie, France). Antibiotic sensitivity was determined by
disc-diffusion method according to the National Committee for
Clinical Laboratory Standard (NCCLS).29 The sensitivity to the
following antibiotics was routinely tested: ampicillin, amoxycillin/
clavulanate, cephalothin, cefuroxime, cefotaxime, ceftazidime,
cefoperazone/sulbactam, piperacillin/tazobactam, imipenem/cilasta-
tin, ciprofloxacin, cotrimoxazole, amikacin, and netilmicin or
gentamicin.
Since 1999, all isolates of E. coli and Klebsiella species were also
tested for the presence of ESBL. ESBL production was phenotypi-
cally determined by combination disc methods, according to the
NCCLS.29 Standard disc-diffusion test using ceftazidime 30 mg and
cefotaxime 30 mg (Oxoid, Basingstoke, UK) was performed. E. coli
and Klebsiella isolates with a zone diameter of p22 and p27 mm
for ceftazidime and cefotaxime, respectively, were considered
suspicious for harboring ESBL. These isolates were retested with
cefotaxime and ceftazidime, alone and in combination with 10mg
clavulanic acid (Oxoid, Basingstoke, UK). A X5 mm increase in
zone diameter for either agent tested in combination with clavulanic
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acid versus its zone when tested alone was confirmed to be ESBL
producing.
Clinical management
Peritonitis episodes were treated with standard antibiotic protocol
from our center at that time, which was changed systemically over
time. Initial antibiotics for peritonitis were generally intraperitoneal
administration of a third- or fourth-generation cephalosporin plus
or minus vancomycin, or cefazolin plus an aminoglycoside or
ceftazidime.5 Antibiotic regimens for individual patients were
modified when culture results were available. When the therapeutic
response to a single antibiotic that the bacterium was sensitive to in
vitro was not satisfactory on day 3 or 5, a second agent was added
(e.g., gentamicin added for cases treated initially with ceftazidime,
and vice versa). In general, patients received antibiotic(s) that the
bacterium isolated was sensitive to in vitro for 14–21 days,
depending on the clinical severity and therapeutic response. Primary
response was defined as resolution of abdominal pain, clearing of
dialysate and PDE neutrophil count less than 100/ml on day 10
with antibiotics alone. When the PDE did not clear up on day 10,
the Tenckhoff catheter was removed immediately, irrespective of the
in vitro sensitivity of the bacterium, and effective antibiotics were
continued for another 2 weeks.
Tenckhoff catheters were removed and patients were put on
temporary hemodialysis when peritonitis failed to resolve with
antibiotics. Tenckhoff catheter reinsertion was attempted in all cases.
In our locality, as described in our previous study,4 patients were
only switched to long-term hemodialysis when attempts of
Tenckhoff catheter reinsertion failed because of peritoneal adhesion,
or when there was ultrafiltration failure due to peritoneal sclerosis.
Relapse peritonitis was defined as an episode that occurs within 4
weeks of completion of therapy of a prior episode with the same
organism (or culture negative).13 Recurrent peritonitis was defined
as an episode that occurs within 4 weeks of completion of therapy of
a prior episode but with a different organism.13 Complete cure was
defined as complete resolution of peritonitis by antibiotics alone
without relapse or recurrence within 4 weeks of completion of
therapy. Repeat peritonitis was defined as an episode that occurs
more than 4 weeks after completion of therapy of a prior episode
with the same organism.13 All the patients were followed for at least
3 months after their treatment completed.
Statistical analysis
Statistical analysis was performed by SPSS for Windows software
version 10.0 (SPSS Inc., Chicago, IL, USA). All data were expressed
in mean7s.d., unless otherwise specified. Data were compared by w2
test, Fisher’s exact test and Student’s t-test as appropriate. Multi-
variate analysis by logistic regression and backward stepwise analysis
were used to test for independent factors that predicted therapeutic
response. All baseline demographic and clinical variables, including
age, sex, duration of dialysis, underlying renal diagnosis, diabetic
status, number of previous peritonitis episode, recent peritonitis
episode, recent antibiotic usage, treatment regimen of the episode
and presence of exit site infection, were included in the model
construction. A P-value of less than 0.05 was considered significant.
All probabilities were two-tailed.
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